



2022 Sustainability Highlights

Conference call for investors and analysts

22 March 2023



Forward-looking statements

In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act of 1995, AstraZeneca (hereafter 'the Group') provides the following cautionary statement: this document contains certain forward-looking statements with respect to the operations, performance and financial condition of the Group, including, among other things, statements about expected revenues, margins, earnings per share or other financial or other measures. Although the Group believes its expectations are based on reasonable assumptions, any forward-looking statements, by their very nature, involve risks and uncertainties and may be influenced by factors that could cause actual outcomes and results to be materially different from those predicted. The forward-looking statements reflect knowledge and information available at the date of preparation of this document and the Group undertakes no obligation to update these forward-looking statements. The Group identifies the forward-looking statements by using the words 'anticipates', 'believes', 'expects', 'intends' and similar expressions in such statements. Important factors that could cause actual results to differ materially from those contained in forward-looking statements, certain of which are beyond the Group's control, include, among other things: the risk of failure or delay in delivery of pipeline or launch of new medicines; the risk of failure to meet regulatory or ethical requirements for medicine development or approval; the risk of failure to obtain, defend and enforce effective IP protection and IP challenges by third parties; the impact of competitive pressures including expiry or loss of IP rights, and generic competition; the impact of price controls and reductions; the impact of economic, regulatory and political pressures; the impact of uncertainty and volatility in relation to the UK's exit from the EU; the risk of failures or delays in the quality or execution of the Group's commercial strategies; the risk of failure to maintain supply of compliant, quality medicines; the risk of illegal trade in the Group's medicines; the impact of reliance on third-party goods and services; the risk of failure in information technology, data protection or cybercrime; the risk of failure of critical processes; any expected gains from productivity initiatives are uncertain; the risk of failure to attract, develop, engage and retain a diverse, talented and capable workforce; the risk of failure to adhere to applicable laws, rules and regulations; the risk of the safety and efficacy of marketed medicines being questioned; the risk of adverse outcome of litigation and/or governmental investigations; the risk of failure to adhere to increasingly stringent anti-bribery and anti-corruption legislation; the risk of failure to achieve strategic plans or meet targets or expectations; the risk of failure in financial control or the occurrence of fraud; the risk of unexpected deterioration in the Group's financial position; and the impact that the COVID-19 global pandemic may have or continue to have on these risks, on the Group's ability to continue to mitigate these risks, and on the Group's operations, financial results or financial condition. Nothing in this document, or any related presentation/webcast, should be construed as a profit forecast.



Sustainability at AstraZeneca

Pam Cheng

EXECUTIVE VICE PRESIDENT, GLOBAL
OPERATIONS, INFORMATION TECHNOLOGY
AND CHIEF SUSTAINABILITY OFFICER



Sustainability Governance at AstraZeneca

Embedding sustainability in everything we do to create value beyond the impact of our medicines

Board of Directors (BOD)



Leif Johansson

Non-Executive Chair of the Board

BOD



Nazneen Rahman

Non-Executive Director of the Board and Chair of the Sustainability Committee

BOD

BSC



Sheri McCoy

Chief Human Resources Officer, Chief Compliance Officer and General Counsel

BOD

BSC



Marcus Wallenberg

Non-Executive Director of the Board

BOD

BSC



Andreas Rummelt

Non-Executive Director of the Board

BOD

BSC

Senior Executive Team (SET)



Pascal Soriot

Executive Director and Chief Executive Officer

BOD

SET



Pam Cheng

Executive Vice President, Global Operations, Information Technology and Chief Sustainability Officer


SET



Jeff Pott

Chief Human Resources Officer, Chief Compliance Officer and General Counsel

SET

 Board of Directors

 Senior Executive Team

 Board Sustainability Committee



Industry-leading efforts in Sustainability

Building a sustainable future for people, society and the planet



Sustainability Ratings



3rd overall
up from 7th in 2020



Bloomberg Gender-Equity Index constituent for 5th consecutive year



A for Climate Change and Water Security



World & Europe constituent



AA MSCI ESG rating maintained since 2014



decreasing ESG Risk Rating since 2019



2022 Sustainability highlights

Progress on our overall strategy includes:

14

public and private sector organisations convened by AstraZeneca CEO through the SMI to accelerate transition to net-zero health systems

87%

of employee survey respondents say that they understand their contributions to our sustainability priorities

25/27

of sustainability targets in Sustainability Data Summary are **'on plan'**

Access to Healthcare

126,684

healthcare workers and others trained¹ (cumulative)

By 2025: 170,000

>44.63m

people reached through Access to Healthcare programmes (cumulative)

By 2025: 50M

>12.83m

people reached through our patient assistance programmes (cumulative)

Environmental protection

59.3%

reduction in Scope 1 and Scope 2 greenhouse gas emissions

By 2026: 98% from 2015 base year

18.7%

reduction in our water use

By 2025: 20% below 2015 baseline

18.6%

reduction in our waste

By 2025: 10% below 2015 baseline

Ethics and transparency

49.5%

senior middle management roles held by women

By 2025: reach gender equality in management positions

8 countries

with supplier diversity programmes

By 2025: 10 new countries outside of the US

83%

of employee survey respondents feel we have a 'speak up' culture





Access to Healthcare

Securing a future of access to affordable, sustainable, and innovative healthcare

Our ambition:

to promote prevention, increase access to life-saving treatments and strengthen global healthcare resilience and sustainability

Our focus:



Innovating

to deliver life-changing medicines and future-proof global health systems



Partnering

to improve health equity for patients now and in the long-term



Transforming

healthcare to secure a future where all people have equitable access to treatment



Partnership for Health System Sustainability and Resilience (PHSSR)

committed to collaborating across sectors and borders to build more

resilient and sustainable health systems

Co-founded by

AstraZeneca

alongside **London School of Economics (LSE)** and the **World Economic Forum (WEF)**

Has expanded to

>30 countries

since its establishment in **2020** with focus on **sustainable healthcare reform**

Access in action: PHSSR impact case studies

Germany

German Healthcare Index created to generate ideas for **targeted interventions** to better adapt to **system shocks**



Japan

Medical Dx platform established — designed for **sharing medical information digitally** — aiming to **improve early diagnosis**



Poland


Health system matrix used to **evaluate implementation of health policies**





Environmental Protection

Progress update on Ambition Zero Carbon



SBTs Target: 98% reduction by 2026

Scope 3

Supplier engagement

Energize collaboration facilitating access to **renewable power at scale**


SMI published **minimum targets** for climate and sustainability

>210
AstraZeneca suppliers registered

12%
of supplier spend in purchased goods and services has **SBTs**

Suppliers¹ with SBTs Targets: 95% by 2025


\$1B Ambition Zero Carbon significant projects:



Next-generation propellant supporting two registrational clinical trials

Other sustainability initiatives including:

- Clean Heat initiatives
- Natural Resources Fund
- Electric vehicle fleet



8 1. 95% of our suppliers by spend covering purchased goods and services and capital goods, and 50% of our suppliers by spend covering upstream transportation and distribution and business travel. Ambition Zero Carbon: reduce our greenhouse gas emissions from our global operations and fleet (Scope 1 and 2) by 98% by early 2026, from 2015 baseline. Reduce our greenhouse gas emissions across our entire value chain footprint (Scope 1, 2 and 3) by 50% by 2030, a 90% reduction by 2045, from 2019 baseline. Our net zero scope 1-3 science-based targets have been verified under the Science Based Targets initiative Net-Zero Corporate Standard. By 2030 we will go even further to become carbon negative for all residual emissions. SMI = Sustainable Markets Initiative.





Natural Resources and Biodiversity at AstraZeneca

Reinforcing our commitment to ensure the sustainable use of natural resources

Approach

adopting principles of the Circular Economy prioritising:



Developing suitable metrics to monitor progress towards a more circular economy



Regenerating nature using renewable natural resources



Minimising amount of material required and waste generated during manufacture and product use



Maximising proportion of waste recycled and aiming to eliminate waste to landfill

Reforestation^{1,2}

committed to:



Plant and maintain 50 million trees worldwide by the end of 2025



Foster biodiversity

planting diverse and locally appropriate species; selecting locations to maximise habitat benefits



Build on existing forest projects

With significant ecological, economic and community co-benefits

- Global AZ Forest Commitments³
- Local tree planting initiatives



10M trees planted since 2020

Water stewardship⁴

through:



A rating for Climate Change and Water Security for 7th consecutive year



Partnership with World Wild Fund of Nature to assess water risks across our operations and value chain



Long-term ambition to implement science-based targets for water

Water footprint -19% since 2015





Ethics and Transparency

Ensuring ethical, open and inclusive behaviour across our organisation and value chain

With a key focus on:



Ethical business culture

I. Human Rights committed to:



United Nations Guiding Principles of **human rights standards**
Global Compact



International Labour Organization Standards on **child labour** and **minimum working age**

II. Responsible supply chain adhering to **Global Standard for the Procurement of Goods and Services**

III. Code of Ethics maintaining **100%** of active employees trained on the **Code of Ethics**



Inclusion and diversity

External Ratings:



FTSE Women Leaders Review 2022: #1 in Pharmaceutical and Biotechnology Sector



Bloomberg Gender Equality Index 2023



Financial Times Diversity Leaders 2023

49.5% females in management positions
By 2025: 50%

17.7% SET and SET-1 are from **emerging markets and Japan**
By 2025: 20%



Workforce safety and health

Committed to:

75%¹

reduction in total injury rate by **2025**

49%²

reduction in collisions per million kilometres driven **since 2015**

with initiatives that include:



Preventing Serious Injury and Fatality (SIF) at Work addressing work at height, safe operation, contractors and construction safety



Healthy Mind app supporting employee mental health, accessed **26,000** times by **16,000** global employees



Drive Success driver safety campaign to protect employees and communities



Question & Answer Session



Pam Cheng

EXECUTIVE VICE PRESIDENT, GLOBAL OPERATIONS, INFORMATION TECHNOLOGY AND CHIEF SUSTAINABILITY OFFICER



Juliette White

VICE PRESIDENT, GLOBAL SHE AND OPERATIONS SUSTAINABILITY



Stefan Weber

GLOBAL HEAD OF POLICY



Bryan Mulchinock

HEAD OF ENVIRONMENT, HEALTH AND SAFETY




Heather Stewart

VICE PRESIDENT, ETHICS AND TRANSPARENCY



John Atkinson

ASSOCIATE DIRECTOR OF COMPLIANCE



Appendix

- [Access to Medicines Index: Performance Summary](#)
- [Access in Action: Healthy Heart Africa](#)
- [Access in Action: Accelerate Change Together](#)






2022 Access to Medicines Index

Continuous improvement across three pillars



access TO
medicine
INDEX

AstraZeneca ATMi Rating History



2022

Score: 3.93

Governance of Access (2nd)

4.43

Research & Development (6th)

3.03

Product Delivery (1st)

4.29

2021

Score: 3.30

Governance of Access (3rd)

4.32

Research & Development (6th)

2.78

Product Delivery (6th)

3.29





Healthy Heart Africa


Improving access to end-to-end hypertension management

Driven by:



Targeted interventions

leveraging existing healthcare systems and initiatives



Focus on hypertension

including screening, diagnosis and treatment




Integrated activities

focused on training healthcare worker and activating healthcare facilities

Our ambition:


to reach **10 million people** with elevated blood pressure across Africa by 2025





Accelerate Change Together

Improving cancer care in Africa



Capacity and capability building

Aiming to improve the quality of care provided to patients across the region through:



supporting
>100
oncology centres



and providing training for
>10,000
healthcare professionals

Enhancing screening and diagnostics

Aiming to cover
1,000,000
patients across three major cancer types:



breast



lung



prostate

Patient empowerment

Advocating for expanded access to screening programmes and removing barriers to innovative medicines around the world by:



ensuring initiatives to **address patient needs**



supporting increased **disease awareness** and **informed patient decision making**

Advancing equitable improvements in cancer outcomes for all



Use of AstraZeneca slides from conference calls and webcasts

The AstraZeneca webcast, conference call and presentation slides (together the 'AstraZeneca materials') are for your personal, non-commercial use only. You may not copy, reproduce, republish, post, broadcast, transmit, make available to the public, sell or otherwise reuse or commercialise the AstraZeneca materials in any way. You may not edit, alter, adapt or add to the AstraZeneca materials in any way, nor combine the AstraZeneca materials with any other material. You may not download or use the AstraZeneca materials for the purpose of promoting, advertising, endorsing or implying any connection between you (or any third party) and us, our agents or employees, or any contributors to the AstraZeneca materials. You may not use the AstraZeneca materials in any way that could bring our name or that of any Affiliate into disrepute or otherwise cause any loss or damage to us or any Affiliate. AstraZeneca PLC, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA. Telephone + 44 20 3749 5000, www.astrazeneca.com

